Delving into the Latest Updates on Suzhong Pharma Group Co. Ltd. with Synapse

Overview

Tags

Neoplasms

Respiratory Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

EGFR L861Q mutation x EGFR S768I mutation x EGFR-G719X	1

Huangkui Capsule is a single medicament of traditional Chinese medicine consists of Abelmoschus manihot and has been widely used to treat kidney disease. The purpose of this study is to evaluate the safety and efficacy of Abelmoschus manihot for treating chronic kidney disease in large scale samples with long time take.

Start Date01 Sep 2014

Sponsor / Collaborator

Chinese People's Liberation Army General Hospital

[+1]

NCT02231125

/ Unknown statusPhase 4IIT

Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial

-IgA nephropathy is the most common primary glomerular disease in China, Huangkui Capsule is a single medicament of traditional Chinese medicine consists of Abelmoschus manihot and has been widely used to treat kidney disease. The purpose of this study is to evaluate the safety and efficacy of Abelmoschus manihot for treating IgA nephropathy in large scale samples with long time take.

Start Date01 Sep 2014

Sponsor / Collaborator

Chinese People's Liberation Army General Hospital

[+1]

CTR20252804

/ Not yet recruitingPhase 3

一项多中心、随机、开放、阳性对照的III期临床研究：评价马来酸苏特替尼胶囊单药对比含铂双药化疗一线治疗晚期、EGFR非经典突变非小细胞肺癌患者的有效性和安全性

[Translation] A multicenter, randomized, open, positive-controlled phase III clinical study: Evaluating the efficacy and safety of sutetinib maleate capsules alone versus platinum-containing doublet chemotherapy as the first-line treatment for patients with advanced non-small cell lung cancer and non-classical EGFR mutations

主要目的：评价马来酸苏特替尼胶囊对比含铂双药化疗治疗局部晚期或转移性EGFR非经典突变NSCLC患者的无进展生存期（PFS，由独立中心影像[IRC]评估，基于实体瘤疗效评价标准第1.1版[RECIST 1.1]）。次要目的：评价马来酸苏特替尼胶囊对比含铂双药化疗的PFS（基于研究者评估）；总生存期（OS）；以及基于IRC评估的：客观缓解率（ORR）、缓解持续时间（DOR）、疾病控制率（DCR）、临床获益率（CBR）。评价马来酸苏特替尼胶囊对比含铂双药化疗治疗局部晚期或转移性NSCLC患者的安全性和耐受性。

[Translation]

Primary objective: To evaluate the progression-free survival (PFS, assessed by independent central imaging [IRC], based on Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1]) of sutetinib maleate capsules versus platinum-based doublet chemotherapy in patients with locally advanced or metastatic EGFR non-classical mutation NSCLC. Secondary objectives: To evaluate PFS (based on investigator assessment) of sutetinib maleate capsules versus platinum-based doublet chemotherapy; overall survival (OS); and objective response rate (ORR), duration of response (DOR), disease control rate (DCR), and clinical benefit rate (CBR) based on IRC assessment. To evaluate the safety and tolerability of sutetinib maleate capsules versus platinum-based doublet chemotherapy in patients with locally advanced or metastatic NSCLC.

Start Date-

Sponsor / Collaborator

Jiangsu Maidu Pharmaceutical Research and Development Co., Ltd.

[+1]

100 Clinical Results associated with Suzhong Pharma Group Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Suzhong Pharma Group Co. Ltd.

Login to view more data

100 Deals associated with Suzhong Pharma Group Co. Ltd.

Login to view more data

100 Translational Medicine associated with Suzhong Pharma Group Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 21 Sep 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3

1

Login to view more data